NYSE$ATR

AptarGroup Inc. · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Aptar delivered strong operational performance driven by growth in proprietary drug delivery systems and prestige and mass fragrance dispensing devices.

AptarGroup reported a 7% increase in reported sales and a 2% increase in core sales. Net income increased by 55% to $84 million. Earnings per share increased by 56% to $1.26, and adjusted earnings per share increased by 39% to $1.39.

  • Reported sales increased 7% and net income increased 55% to $84 million
  • Core sales increased 2% and adjusted EBITDA of $193 million increased 26% from the prior year
  • Pharma proprietary drug delivery systems had double-digit growth across multiple therapeutic applications
  • Beauty’s prestige and mass fragrance dispensing technologies had double-digit sales growth

Headline financials

Total Revenue

$893M

Previous: $837M+6.7%
EPS (adj)

$1.39

Previous: $0.95+46.3%
Total Core Sales Growth

2.0%

Previous: 9.0%-77.8%
Pharma Core Sales Growth

8.0%

Previous: 20.0%-60.0%
Beauty Core Sales Growth

2.0%

Previous: 4.0%-50.0%
Closures Core Sales Growth

-9.0%

Previous: 0.0%
Capital Expenditures

-$231M

Previous: -$226M-2.2%
Free Cash Flow

-$147M

Previous: -$172M+14.5%
Net Income

$84.3M

Previous: $54.2M+55.4%
Operating Income

$119M

Previous: $95.2M+25.4%
Gross Profit

$893M

Previous: $837M+6.7%
Cash & Equivalents

$152M

Previous: $125M+21.4%
Total Assets

$4.3B

Previous: $4.03B+6.7%
Stock-Based Comp

$10.7M

Previous: $9.81M+8.6%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$893M

Q3 2023+6.7%vs Q3 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

AptarGroup · $893M total across 3 segments · Q3 2023

  • Pharma
    $389M+13.3%
  • Beauty
    $324M-10.0%
  • Closures
    $180M+34.6%

Forward guidance

Aptar expects continued growth in proprietary pharma drug delivery systems and improvement in the injectables division. Fragrance dispensing solutions are anticipated to finish strong in 2023. The Beauty and Closures segments will be aided by the improving environment in North America.

Tailwinds

  • Continued growth in proprietary pharma drug delivery systems
  • Continued improvement in injectables division’s performance
  • Fragrance dispensing solutions expected to finish strong in 2023
  • Beauty and Closures segments aided by improving environment in North America
  • Focus on reducing costs and driving profitable growth

Headwinds

  • Guidance excludes restructuring expenses
  • Guidance excludes changes in the fair value of equity investments
  • Guidance excludes acquisition costs
  • Guidance is based on an effective tax rate range of 24% to 26%
  • Currency exchange rate assumptions equate to an approximately $0.02 per share tailwind when compared to the prior year fourth quarter earnings.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro